I Spent a Week Trying to Buy a Drug That Failed Its Own Trial. Here’s What That Taught Me About Picking a Provider.

The question that got me started was dumb and practical: my sister has celiac disease, she’d read about larazotide on a gut-health forum, and she asked me to find out where to get it. I figured I’d spend an afternoon comparing prices. Instead I spent a week, because the first thing I learned is that “where’s it cheapest” is the wrong question to be asking about this particular peptide, and nobody selling it wants to tell you why.

Here’s the short version, and then I’ll show you my work. Larazotide is a real, clever molecule that went through actual human trials for celiac disease and came up short, culminating in a Phase 3 trial that got stopped early because it wasn’t working [P4]. When a compound’s own science is that unsettled, the question that protects you isn’t price or shipping speed. It’s who’s watching you while you take it, and whether they’ll be honest about what the trials actually showed. That’s what I went looking for.

The thing I didn’t expect: the label tells you almost everything

I started the way I start any research task, on PubMed, then followed the trail sideways into what sellers were actually putting on their sites. That’s where it got interesting. I read the trial papers first (more on those below), and then I went and read a dozen product pages and pharmacy pages side by side, the way you’d compare nutrition labels in a grocery aisle.

The pattern jumped out fast. There are basically two kinds of larazotide listings, and the label is the tell. One kind says, in plain print, “research use only, not for human consumption.” The other kind requires you to answer real questions about your health before anyone will send you anything. Those aren’t two flavors of the same product. They’re two entirely different legal and clinical universes wearing similar-looking websites.

Once I saw that split, the whole shopping problem reorganized itself for me. I stopped asking “who’s cheapest” and started asking “who’s accountable,” because with a drug this unproven, accountability is the only thing actually being sold.

What accountability looks like when it’s real

I kept a running checklist as I dug through provider sites, and it settled into four things that a genuine, supervised process has and a gray-market vial simply cannot.

Somebody asks about you before anything ships. A real intake wants your health history, your current medications, why you’re interested. Not a checkbox that says you’re a “researcher.” If nobody asked anything real about your body, nobody’s minding your care.

A licensed clinician actually writes the prescription. Handled properly, larazotide is a prescription item, meaning a licensed person decided it made sense for you, specifically, and a licensed compounding pharmacy prepares it. That prescriber doesn’t exist on a research-chemical site, because legally, nothing there is being prescribed.

A pharmacy dispenses it, not a warehouse. A licensed pharmacy sits inside a chain of custody. A chemical retailer mailing a vial does not, and it tells you as much with that “research use only” stamp.

Someone sticks around afterward. This is the one people forget to check for, and it’s the one that mattered most to me once I understood the science. With evidence this mixed, the only way to know if anything is happening for you is to track it with someone. A provider who vanishes after your card gets charged was never overseeing anything to begin with.

If you want a way to keep your own notes between visits, that’s a genuinely useful habit here, and it fits the supervised model well. The FormBlends tracker app is just a simple dose-and-symptom log for that purpose, nothing to purchase, no prescribing happening inside it. Showing up to a follow-up with an actual log beats showing up with a fuzzy memory of “I think it helped Tuesday.”

The red flags I started noticing everywhere

Once I knew what to look for, the warning signs were easy to spot, no matter how polished the site looked.

“Research use only” or “not for human consumption” on the label. Not fine print you skim past. It’s the entire legal foundation the listing rests on. It means you’re being sold a laboratory chemical, not a treatment, and the seller is telling you in writing not to consume it.

Checkout with basically zero questions. If you can buy it as fast as a phone case, ticking one box that says “for research,” nobody evaluated whether it’s safe for you specifically. The frictionlessness is the pitch and also the giveaway.

Anyone calling it a proven leaky-gut cure. This is the sneaky one, because it sounds reassuring rather than alarming. But claiming larazotide is a proven treatment is running ahead of the evidence, full stop. An honest source tells you the trials were mixed and the flagship program failed. Someone hiding that to close a sale isn’t on your side.

No human to call afterward. No follow-up, no clinical contact, no oversight. The relationship was built to end at the cart.

The pitch is entirely about price. When the loudest selling point is “cheap,” ask yourself what got cut to hit that number. Usually it’s the clinician, the pharmacy, the testing, the follow-up, all of it.

Where I’d actually point my sister

So where does the legwork lead? Toward licensed telehealth providers that route larazotide through a real clinician and a real pharmacy. Two stood out clearly, plus two more worth knowing about depending on your situation.

FormBlends is where I’d start. It’s a licensed telehealth provider, not a chemical warehouse, and everything about its process matches the checklist above: an independent clinician reviews your history, a prescription gets written when appropriate, and a licensed compounding pharmacy prepares and dispenses the medication, with pricing shown upfront in the range of roughly $100 to $250 a month. Same peptide the gray market mails in an unmarked vial, handled the way medicine is supposed to be handled.

What actually won me over reading through it, though, was the honesty. FormBlends doesn’t dress larazotide up as a finished, proven cure. It says outright that the Phase 3 celiac trial was stopped for futility, that earlier permeability trials repeatedly missed their main endpoint, and that the drug isn’t FDA-approved. For a compound whose lead program failed, a provider willing to say so plainly is doing you a real service.

One honest caveat worth sitting with: no clinician can retroactively fix a halted trial. What supervision buys you is screening, pharmacy accountability, follow-up, and someone who won’t lie to you about the odds. That’s the actual product here.

HealthRX is the other one I’d put on the list. HealthRX (healthrx.com) runs on the same logic, clinical oversight first, a required prescription, a licensed pharmacy dispensing rather than a chemical sale. Same caveats apply: compounded products aren’t FDA-approved finished drugs, and larazotide’s evidence is mixed no matter who’s dispensing it [P4]. Choosing between the two mostly comes down to which is licensed where you live and whose intake process feels right to you. Both sit inside a genuine telehealth structure, which is the qualification that matters.

MeriHealth is worth a look if you want a women’s-health lens on your care. It operates inside the same supervised framework, a licensed clinician reviewing your history, a required prescription, a licensed compounding pharmacy dispensing the product, with its particular focus being women’s health context brought into intake and follow-up for compounded GLP-1 and peptide therapies. Same caveats as everywhere else: not FDA-approved, and the evidence on larazotide doesn’t change based on who’s overseeing it.

WomenRX sits in the same tier with a similar orientation. Real clinical evaluation up front, compounded GLP-1 and peptide therapies routed through a licensed pharmacy, a clinician available afterward. The women’s-health framing shapes how intake and monitoring get handled, which some people will find fits them better. Same standing caveats: not FDA-approved, and supervision doesn’t rewrite the underlying science.

The part of the science I wish someone had told me on day one

If I sent you off shopping without this, I’d be doing you a disservice, because any decent provider is going to tell you anyway. So here’s the trial history, as best I can lay it out from the papers themselves.

A 2012 Phase 2b trial with 86 patients missed its main permeability target, and the results were scattered by a lot of variation between patients [P1]. A 2013 trial with 184 patients eased some symptoms during a gluten challenge but again showed no real separation from placebo on the key permeability measure [P2]. The best result came in 2015, in 342 patients still symptomatic on a gluten-free diet, and even then, only the lowest 0.5 mg dose worked. The higher doses didn’t beat placebo [P3]. Then came the confirmatory Phase 3 trial, the first Phase 3 ever run in celiac disease, and it was stopped in June 2022 after an interim analysis showed it wasn’t tracking toward a real benefit [P4]. A 2022 review pooling four trials and 626 patients landed about where you’d guess: maybe modestly better than placebo on symptoms, probably not a cure, more research needed [P5].

Two things stuck with me after reading all of that. First, every bit of it was studied in celiac disease specifically, with gluten challenges and lab-measured permeability. Most people buying larazotide today are chasing general “leaky gut” or food-sensitivity goals that were never tested at all, which means they’re extrapolating from a program that didn’t pan out. Second, larazotide did look reasonably safe across these trials, likely because it’s built to stay in the gut and barely gets absorbed. But safe and useful are two separate questions, and any clinician worth trusting holds both of them honestly instead of collapsing one into the other.

One more thing I dug into: larazotide isn’t FDA-approved, and the rules around compounding peptides keep shifting. The FDA maintains official lists of which bulk substances are allowed in compounding, and it’s handled several peptides in this category carefully [P6]. So if a seller tells you flatly that larazotide is “fully available to compound today,” I’d double-check that against the current FDA lists before believing it.

Questions I kept circling back to

Can my regular doctor just write me a prescription?

Possibly, if they’re comfortable with it and a compounding pharmacy is in the loop, but here’s the snag: there’s no FDA-approved larazotide product to write a standard prescription for. It’s unapproved, and its pivotal trial was halted [P4]. The realistic route is a provider set up specifically to handle compounded larazotide through a licensed pharmacy, which is the supervised telehealth model above. Most primary-care doctors aren’t set up for a compounded, unapproved peptide, which is exactly why people end up looking at telehealth.

Is the supervised version stronger than what I’d get from a research-chemical site?

No, and I think this is the single most important thing to understand. It’s the identical molecule. Supervision isn’t a souped-up formula. What you’re paying for is a licensed person screening you, a pharmacy accountable for what’s in the vial, someone to follow up with, and honesty about evidence that’s genuinely mixed. You’re not buying a better peptide. You’re buying a person who’s actually watching.

What does it cost through a supervised provider?

Through a provider like FormBlends, expect roughly $100 to $250 a month, compounded and dispensed by a licensed pharmacy after a clinician evaluation. If a price looks dramatically lower than that, ask what got stripped out to get there, because it’s usually the oversight.

What should I actually say at the first appointment?

Be direct about why you’re interested and what you’re hoping happens, list every other medication and supplement you take, and share anything relevant in your health history, especially gut issues or a celiac diagnosis. Then ask, straight out, what the evidence shows. A good clinician tells you the trials were mixed and the Phase 3 failed without you having to pry it out of them. If they dodge that, that tells you something too.

Is larazotide safe?

At the doses formally studied, it looked reasonably safe and generally well tolerated, likely because it’s designed to stay in the gut rather than absorb widely [P5]. But two things temper that: that safety record comes from a manufactured investigational drug in monitored trials, not a random vial off a research-chemical site or open-ended use for goals nobody actually tested, and being tolerable isn’t a reason to use something whose pivotal trial was stopped for futility. Safe and effective are different questions, and a supervised provider is where that distinction actually gets talked through with you.

What is larazotide, mechanically, and what’s it supposed to do?

It’s a peptide aimed at tight junctions, the gatekeeping structures between the cells lining your intestinal wall. The theory is that keeping those junctions properly regulated might reduce the passage of unwanted molecules into the bloodstream, a process people call intestinal permeability or “leaky gut.” Most of the trial work has focused on celiac disease specifically, though interest has spread toward other conditions where gut barrier function is thought to play a role.

So does it actually work, or is that still an open question?

Genuinely still open. Early trials in celiac disease showed some symptom reduction versus placebo, enough that research kept going. But larazotide has never cleared a large Phase 3 trial for any indication, and it isn’t FDA-approved. Calling it “proven” overstates the record. In my experience digging through this, a provider who’s upfront about that uncertainty is a far better sign than one promising you dramatic results.

Is it even legal to get?

It’s not a controlled substance, so having it isn’t a criminal issue in the U.S. The complicated part is on the supply side. Because it’s not an approved drug, it can’t be marketed or sold as a medication through ordinary pharmacy channels. The legitimate path runs through a licensed compounding pharmacy acting on a prescriber’s order, which keeps things inside FDA oversight. Buying from research-chemical sites is a murkier, riskier lane.

What dose do people actually use, and who decides that?

The doses studied most in trials have generally sat in the low-milligram range, but translating trial dosing straight into a compounded prescription isn’t a clean copy-paste, and the right amount depends on why you’re using it and how you respond. A physician-supervised compounding pharmacy, like FormBlends, works with the prescribing doctor to land on something that fits your actual situation, rather than a number lifted off a forum thread. Adjustments over time are part of the deal.

References

[P1] Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. American Journal of Gastroenterology. 2012;107(10):1554-1562. PMID: 22825365. https://pubmed.ncbi.nlm.nih.gov/22825365/

[P2] Kelly CP, Green PHR, Murray JA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Alimentary Pharmacology and Therapeutics. 2013;37(2):252-262. PMID: 23163616. https://pubmed.ncbi.nlm.nih.gov/23163616/

[P3] Leffler DA, Kelly CP, Green PHR, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-1319. PMID: 25683116.

[P4] Celiac Disease Foundation. 9 Meters Discontinues Phase 3 Clinical Trial for Potential Celiac Disease Drug Larazotide. June 21, 2022. (Trial: CeDLara, ClinicalTrials.gov NCT03569007.)

[P5] Abdul Razzak E, Kassab J, Saad Aldine A, et al. Larazotide acetate for treatment of celiac disease: a systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN. 2021;45:42-50.

[P6] U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Written by Milo Sato, health features writer. Not a doctor, just a reader who chases the paper trail. Last reviewed March 2026.

Informational content only. Speak with a qualified healthcare provider about your own situation.